BTI
KRYS icon

Blue Trust Inc’s Krystal Biotech KRYS Stock Holding History

Blue Trust Inc’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$1.03K – 2566
2026
Q1 		$1.03K Hold
4
– – ﹤0.01% 2255
2025
Q4 		$986 Sell
4
-2
-33% -$421 ﹤0.01% 2287
2025
Q3 		$1.06K Hold
6
– – ﹤0.01% 2310
2025
Q2 		$825 Sell
6
-3
-33% -$441 ﹤0.01% 2270
2025
Q1 		$1.62K Buy
9
+6
+200% +$1.01K ﹤0.01% 2239
2024
Q4 		$470 Sell
3
-579
-99% -$103K ﹤0.01% 2329
2024
Q3 		$107K Buy
582
+412
+242% +$79.4K ﹤0.01% 1185
2024
Q2 		$30.2K Buy
170
+163
+2,329% +$27.4K ﹤0.01% 1490
2024
Q1 		$1.25K Buy
+7
New +$972 ﹤0.01% 1903

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Blue Trust Inc's KRYS Position: Q2 2026 in Review

Blue Trust Inc sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 4 shares — an estimated $1.03K sold.

Blue Trust Inc first reported a position in KRYS in Q1 2024 and held it in 9 quarters. The position peaked at $107K in Q3 2024. 422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Blue Trust Inc reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Blue Trust Inc sold 4 Krystal Biotech shares in Q2 2026, an estimated $1.03K.
  • Blue Trust Inc first reported a position in Krystal Biotech in Q1 2024 and held it in 9 quarters.
  • Blue Trust Inc's Krystal Biotech position peaked at $107K in Q3 2024.
  • 422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.